← 產業報告目錄

Companion Diagnostic Market Research Report by Test Type (HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, Others), by Products & Services (Assays, Reagents & Kits, Instruments/Systems, Software & Services), by Technology [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), Others], by Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Infectious Disease), by End User (Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, Others), and by Region (North America, Europe, Asia-Pacific) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-03-26頁數 239報告編號 MRFRMED2231CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The global companion diagnostic market is projected to reach a value of USD 25,300.58 million by 2035, reflecting strong growth momentum over the forecast period. Expanding at a CAGR of 12.68% from 2025 to 2035, the market is being driven by the increasing adoption of personalized medicine and targeted therapies. Surging Burden of Cancer and Chronic Diseases The rapidly increasing incidence of cancer and chronic conditions worldwide is a primary driver of the global companion diagnostics market, as it intensifies the need for precision medicine and targeted treatment strategies. This growing disease burden is accelerating the adoption of biomarker-based diagnostics to improve clinical outcomes and optimize therapy selection. Segment-wise Snapshot of the Market • HER2 Testing – Guides targeted breast cancer therapy decisions • PD-1 Testing – Enables immunotherapy response assessment in cancers • EGFR Mutation Testing – Identifies lung cancer targeted treatment suitability • ALK Rearrangement Testing – Detects gene fusions for precision oncology • Others (Test Type) – Covers emerging biomarker-based diagnostic assays • Assays – Core diagnostic tools for biomarker detection • Reagents & Kits – Essential consumables supporting diagnostic testing workflows • Instruments/Systems – Platforms enabling accurate and efficient diagnostics • Software & Services – Data analysis and clinical support solutions • PCR – Rapid amplification for sensitive genetic mutation detection • NGS – High-throughput sequencing for comprehensive genomic profiling • IHC – Protein expression analysis in tissue-based diagnostics • FISH – Detects chromosomal abnormalities using fluorescent probes • Others (Technology) – Includes advanced and hybrid diagnostic technologies • Cancer – Dominant application driven by rising global incidence • Neurological Disorders – Supports diagnosis of complex brain conditions • Cardiovascular Disorders – Enables risk assessment and targeted treatments • Infectious Disease – Assists in pathogen detection and therapy selection • Biopharmaceutical and Biotechnology Companies – Drive co-development of targeted therapies • CROs and CDMOs – Provide outsourced research and manufacturing support • Others (End User) – Includes hospitals, diagnostic labs, and research institutes Regional Growth Overview North America dominates due to a rising cancer survivor base and strong regulatory support accelerating companion diagnostics adoption. Europe and Asia Pacific are witnessing rapid growth driven by stricter regulations, expanding clinical evidence, and increasing cancer burden. Strategic Launch of Clinical-Grade dPCR Platform In September 2024, QIAGEN introduced the QIAcuityDx, a clinical-grade digital PCR system designed for oncology and liquid biopsy applications, offering precise quantitation of low-abundance DNA/RNA. With regulatory alignment under U.S. 510(k) exemption and Europe’s IVDR, the platform strengthens its companion diagnostics pipeline through enhanced workflow integration and expanding pharma partnerships. Expansion into Non-Oncology Therapeutic Areas The global companion diagnostics market is gaining a strategic edge by expanding beyond oncology into metabolic, cardiovascular, and rare genetic diseases, significantly broadening its application scope. This shift is unlocking new growth avenues as biomarker-driven approaches begin addressing a wider patient population. Key Report Attributes • Market Size 2035: USD 25,300.58 Million • CAGR (2025-2035): 12.68% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Test Type: HER2 Testing - 10.90%, PD-1 Testing - 12.03%. • By Products & Ser5vices: Assays - 12.27%, Reagents & Kits - 12.99%. • By Technology: Polymerase Chain Reaction (PCR) -12.95%, Next-Generation Sequencing (NGS) - 13.91%. • By Indication: Cancer - 12.67%, Neurological Disorders - 11.93%. • By End User: Biopharmaceutical and Biotechnology Companies - 12.35%, CROs and CDMOs - 13.91%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ............. 20 2 MARKET INTRODUCTION .......... 22 2.1 DEFINITION ........ 22 2.2 SCOPE OF THE STUDY ......... 22 2.3 RESEARCH OBJECTIVE ....... 22 2.4 MARKET STRUCTURE ......... 23 3 RESEARCH METHODOLOGY ........... 25 3.1 OVERVIEW .......... 25 3.2 DATA FLOW ........ 27 3.2.1 DATA MINING PROCESS .......... 27 3.3 PURCHASED DATABASE: ........... 28 3.4 SECONDARY SOURCES: ....... 29 3.4.1 SECONDARY RESEARCH DATA FLOW: ........... 30 3.5 PRIMARY RESEARCH: .......... 31 3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 32 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 33 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ....... 34 3.6.1 REVENUE ANALYSIS APPROACH ............ 34 3.7 DATA FORECASTING............ 35 3.7.1 DATA FORECASTING TYPE ....... 35 3.8 DATA MODELING ............ 36 3.8.1 MICROECONOMIC FACTOR ANALYSIS: .......... 36 3.8.2 DATA MODELING: ............. 37 3.9 TEAMS AND ANALYST CONTRIBUTION ......... 39 4 MARKET DYNAMICS ........... 41 4.1 INTRODUCTION ........ 41 4.2 DRIVERS ........ 42 4.2.1 RISING CANCER & CHRONIC DISEASE PREVALENCE ........... 42 4.2.2 GROWING ADOPTION OF TARGETED THERAPIES AND PRECISION MEDICINE .......... 43 4.2.3 TECHNOLOGICAL ADVANCES ......... 43 4.2.4 INCREASING DRUG–DIAGNOSTIC CO-DEVELOPMENT & REGULATORY APPROVALS ....... 44 4.3 RESTRAINTS ............. 45 4.3.1 HIGH COST & CAPITAL INVESTMENT FOR CDX DEVELOPMENT AND TESTING ........ 45 4.3.2 REGULATORY COMPLEXITY AND VARIED APPROVAL PATHWAYS ............ 45 4.3.3 LIMITED REIMBURSEMENT, UNEVEN ACCESS & AWARENESS ............ 45 4.4 OPPORTUNITIES ............. 47 4.4.1 EXPANSION BEYOND ONCOLOGY INTO OTHER THERAPEUTIC AREAS ............. 47 4.4.2 GROWTH IN BIOINFORMATICS, SOFTWARE & SERVICES SUPPORTING CDX............. 47 5 MARKET FACTOR ANALYSIS ........... 49 5.1 PORTER'S FIVE FORCES MODEL ........... 49 5.1.1 THREAT OF NEW ENTRANTS ........... 49 5.1.2 BARGAINING POWER OF SUPPLIERS ............. 50 5.1.3 THREAT OF SUBSTITUTES ....... 50 5.1.4 BARGAINING POWER OF BUYERS ........... 50 5.1.5 INTENSITY OF RIVALRY ........... 50 5.2 IMPACT ANALYSIS OF COVID-19 .......... 51 5.2.1 DISRUPTION IN DIAGNOSTIC TESTING AND ONCOLOGY PROCEDURES ............ 51 5.2.2 SUPPLY CHAIN DISRUPTIONS ......... 51 5.2.3 CHANGES IN PATIENT BEHAVIOR AND CLINICAL WORKFLOWS ......... 51 5.2.4 IMPACT ON R&D AND INNOVATION ........ 52 5.3 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO ......... 53 5.4 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION) ............ 55 5.5 MARKET SHARE BY DRUG GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%) ......... 55 5.5.1 GLOBAL MARKET SHARE BY DRUG, 2024 (%) ........ 55 5.5.2 NORTH AMERICA MARKET SHARE BY DRUG, 2024 (%) ........ 56 5.5.2.1 US MARKET SHARE BY DRUG, 2024 (%) ........ 56 5.5.3 EUROPE MARKET SHARE BY DRUG, 2024 (%) ........ 57 5.5.3.1 GERMANY MARKET SHARE BY DRUG, 2024 (%) ........... 57 5.5.3.2 UK MARKET SHARE BY DRUG, 2024 (%) ........ 58 5.5.4 ASIA-PACIFIC MARKET SHARE BY DRUG, 2024 (%) ....... 58 5.5.4.1 CHINA MARKET SHARE BY DRUG, 2024 (%) ......... 59 5.5.4.2 INDIA MARKET SHARE BY DRUG, 2024 (%) ........... 59 5.5.4.3 JAPAN MARKET SHARE BY DRUG, 2024 (%) ......... 60 5.6 MARKET SHARE BY CLONE GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%) ....... 61 5.6.1 GLOBAL MARKET SHARE BY CLONE, 2024 (%) ............. 61 5.6.2 NORTH AMERICA MARKET SHARE BY CLONE, 2024 (%) ............. 61 5.6.2.1 US MARKET SHARE BY CLONE, 2024 (%) ............. 62 5.6.3 EUROPE MARKET SHARE BY CLONE, 2024 (%) ............. 62 5.6.3.1 GERMANY MARKET SHARE BY CLONE, 2024 (%) ......... 63 5.6.3.2 UK MARKET SHARE BY CLONE, 2024 (%) ............. 63 5.6.4 ASIA-PACIFIC MARKET SHARE BY CLONE, 2024 (%) ............ 64 5.6.4.1 INDIA MARKET SHARE BY CLONE, 2024 (%) ......... 64 5.6.4.2 JAPAN MARKET SHARE BY CLONE, 2024 (%) ....... 65 5.7 QUALITATIVE ANALYSIS OF PD-L1 TESTING CUT-OFFS ............. 66 5.8 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION .......... 67 5.9 PRICING ANALYSIS, 2024 (USD) ............ 67 6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE ........... 69 6.1 OVERVIEW .......... 69 6.2 HER2 TESTING ......... 72 6.3 PD-1 TESTING ............ 73 6.4 EGFR MUTATION TESTING ............. 74 6.5 ALK REARRANGEMENT TESTING ....... 74 6.6 OTHERS ......... 74 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES ......... 76 7.1 OVERVIEW .......... 76 7.2 ASSAYS, REAGENTS & KITS ............ 78 7.3 INSTRUMENTS/SYSTEMS ........ 78 7.4 SOFTWARE & SERVICES ............ 79 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY ............ 80 8.1 OVERVIEW .......... 80 8.2 POLYMERASE CHAIN REACTION (PCR) ........... 82 8.3 NEXT-GENERATION SEQUENCING (NGS) ........ 82 8.4 IMMUNOHISTOCHEMISTRY (IHC) ....... 83 8.5 FLUORESCENCE IN-SITU HYBRIDIZATION (FISH)............. 83 8.6 OTHERS ......... 83 9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION .......... 84 9.1 OVERVIEW .......... 84 9.2 CANCER......... 86 9.3 NEUROLOGICAL DISORDERS ............ 87 9.4 CARDIOVASCULAR DISORDERS............. 87 9.5 INFECTIOUS DISEASES ........ 88 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER ............ 89 10.1 OVERVIEW .......... 89 10.2 BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ............ 91 10.3 CROS AND CDMOS .......... 91 10.4 OTHERS ......... 92 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION ......... 93 11.1 OVERVIEW .......... 93 11.2 NORTH AMERICA ........... 95 11.2.1 US........ 102 11.2.2 CANADA ............ 106 11.3 EUROPE ......... 111 11.3.1 GERMANY .......... 119 11.3.2 FRANCE ............. 123 11.3.3 UK ....... 127 11.3.4 ITALY .......... 131 11.3.5 SPAIN ......... 135 11.3.6 DENMARK .......... 139 11.3.7 FINLAND ............ 143 11.3.8 ICELAND ............ 147 11.3.9 NORWAY ............ 151 11.3.10 SWEDEN ............ 155 11.3.11 REST OF EUROPE ....... 159 11.4 ASIA-PACIFIC ............ 164 11.4.1 INDIA .......... 172 11.4.2 JAPAN ........ 176 11.4.3 SOUTH KOREA ........... 180 11.4.4 AUSTRALIA ........ 184 11.4.5 REST OF ASIA-PACIFIC ............ 188 12 COMPETITIVE LANDSCAPE ............. 193 12.1 INTRODUCTION ........ 193 12.2 MARKET SHARE ANALYSIS, 2024 ....... 193 12.3 COMPETITOR DASHBOARD....... 194 12.4 PUBLIC PLAYERS STOCK SUMMARY ........ 195 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ........ 195 12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ........ 196 12.1.1 PRODUCT/SERVICE LAUNCH ........... 196 12.1.2 ACQUISITION ............ 197 12.1.3 ACCREDITATION ....... 198 12.1.4 COLLABORATION/ PARTNERSHIP .......... 199 13 COMPANY PROFILES ......... 200 13.1 QIAGEN .......... 200 13.1.1 COMPANY OVERVIEW ....... 200 13.1.2 FINANCIAL OVERVIEW ............. 201 13.1.3 PRODUCTS OFFERED ........ 202 13.1.4 KEY DEVELOPMENTS ........ 202 13.1.5 SWOT ANALYSIS ....... 203 13.1.6 KEY STRATEGIES ....... 204 13.2.4 PRODUCTS OFFERED ........ 208 13.2.6 SWOT ANALYSIS ....... 209 13.3 BIOMÉRIEUX ............. 211 13.3.1 COMPANY OVERVIEW ....... 211 13.3.2 FINANCIAL OVERVIEW ............. 212 13.3.3 PRODUCTS OFFERED ........ 213 13.3.4 KEY DEVELOPMENTS ........ 214 13.3.5 SWOT ANALYSIS ....... 215 13.3.6 KEY STRATEGIES ....... 215 13.4 LEICA BIOSYSTEMS NUSSLOCH GMBH ............ 216 13.4.1 COMPANY OVERVIEW ....... 216 13.4.2 FINANCIAL OVERVIEW ............. 216 13.4.3 PRODUCTS OFFERED ........ 217 13.4.4 KEY DEVELOPMENTS ........ 217 13.4.5 KEY STRATEGIES ....... 217 13.5 NG BIOTECH ....... 218 13.5.1 COMPANY OVERVIEW ....... 218 13.5.2 FINANCIAL OVERVIEW ............. 219 13.5.3 PRODUCTS OFFERED ........ 219 13.5.5 KEY STRATEGIES ....... 219 13.6 THERMO FISHER SCIENTIFIC INC. ....... 220 13.6.1 COMPANY OVERVIEW ....... 220 13.6.2 FINANCIAL OVERVIEW ............. 221 13.6.3 PRODUCTS OFFERED ........ 222 13.6.4 KEY DEVELOPMENTS ........ 222 13.6.5 SWOT ANALYSIS ....... 223 13.6.6 KEY STRATEGY .......... 223 13.7 ILLUMINA, INC. ........ 224 13.7.1 COMPANY OVERVIEW ....... 224 13.7.2 FINANCIAL OVERVIEW ............. 225 13.7.3 PRODUCTS OFFERED ........ 226 13.7.4 KEY DEVELOPMENTS ........ 226 13.7.5 KEY STRATEGIES ....... 227 13.8 AGILENT TECHNOLOGIES, INC. ............. 228 13.8.1 COMPANY OVERVIEW ....... 228 13.8.2 FINANCIAL OVERVIEW ............. 229 13.8.3 PRODUCTS OFFERED ........ 230 13.8.4 KEY DEVELOPMENTS ........ 230 13.8.5 SWOT ANALYSIS ....... 231 13.8.6 KEY STRATEGIES ....... 231 13.9 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ) ............. 232 13.9.1 COMPANY OVERVIEW ....... 232 13.9.2 FINANCIAL OVERVIEW ............. 233 13.9.3 PRODUCTS OFFERED ........ 234 13.9.4 KEY DEVELOPMENTS ........ 234 13.9.5 KEY STRATEGIES ....... 234 13.10 MYRIAD GENETICS, INC. ............ 235 13.10.1 COMPANY OVERVIEW ....... 235 13.10.2 FINANCIAL OVERVIEW ............. 236 13.10.3 PRODUCTS OFFERED ........ 236 13.10.4 KEY DEVELOPMENTS ........ 237 13.10.5 KEY STRATEGIES ....... 237 14 DATA CITATIONS ......... 238
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 38 TABLE 2 COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO 53 TABLE 3 PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION) 55 TABLE 4 PD-L1 TESTING CUT-OFFS 66 TABLE 5 PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION 67 TABLE 6 PRICING ANALYSIS, 2024 (USD) 67 TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION) 70 TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (TEST VOLUME) 71 TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (USD MILLION) 72 TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (TEST VOLUME) 72 TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION) 77 TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION) 81 TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 & 2035 (USD MILLION) 85 TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 & 2035 (USD MILLION) 90 TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (USD MILLION) 93 TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (TEST VOLUME) 94 TABLE 17 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 97 TABLE 18 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 98 TABLE 19 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 99 TABLE 20 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 99 TABLE 21 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 100 TABLE 22 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 100 TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 101 TABLE 24 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 101 TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 102 TABLE 26 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 102 TABLE 27 US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 103 TABLE 28 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 103 TABLE 29 US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 104 TABLE 30 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 104 TABLE 31 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 105 TABLE 32 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 105 TABLE 33 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 106 TABLE 34 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) 106 TABLE 35 CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) 107 TABLE 36 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION) 107 TABLE 37 CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME) 108 TABLE 38 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION) 108 TABLE 39 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION) 109 TABLE 40 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION) 109 TABLE 41 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION) 110 TABLE 42 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 113 TABLE 43 EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-H-2035 (TEST VOLUME) 114 TABLE 44 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 115 TABLE 45 EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 116 TABLE 46 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 116 TABLE 47 EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 117 TABLE 48 EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 117 TABLE 49 EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 118 TABLE 50 EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 118 TABLE 51 EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 119 TABLE 52 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 119 TABLE 53 GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 120 TABLE 54 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 120 TABLE 55 GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 121 TABLE 56 GERMANY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 121 TABLE 57 GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 122 TABLE 58 GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 122 TABLE 59 GERMANY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 123 TABLE 60 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 123 TABLE 61 FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 124 TABLE 62 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 124 TABLE 63 FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 125 TABLE 64 FRANCE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 125 TABLE 65 FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 126 TABLE 66 FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 126 TABLE 67 FRANCE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 127 TABLE 68 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 127 TABLE 69 UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 128 TABLE 70 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 128 TABLE 71 UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 129 TABLE 72 UK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 129 TABLE 73 UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 130 TABLE 74 UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 130 TABLE 75 UK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 131 TABLE 76 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 131 TABLE 77 ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 132 TABLE 78 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 132 TABLE 79 ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 133 TABLE 80 ITALY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 133 TABLE 81 ITALY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 134 TABLE 82 ITALY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 134 TABLE 83 ITALY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 135 TABLE 84 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 135 TABLE 85 SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 136 TABLE 86 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 136 TABLE 87 SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 137 TABLE 88 SPAIN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 137 TABLE 89 SPAIN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 138 TABLE 90 SPAIN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 138 TABLE 91 SPAIN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 139 TABLE 92 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 139 TABLE 93 DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 140 TABLE 94 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 140 TABLE 95 DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 141 TABLE 96 DENMARK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 141 TABLE 97 DENMARK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 142 TABLE 98 DENMARK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 142 TABLE 99 DENMARK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 143 TABLE 100 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 143 TABLE 101 FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 144 TABLE 102 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 144 TABLE 103 FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 145 TABLE 104 FINLAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 145 TABLE 105 FINLAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 146 TABLE 106 FINLAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 146 TABLE 107 FINLAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 147 TABLE 108 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 147 TABLE 109 ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 148 TABLE 110 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 148 TABLE 111 ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 149 TABLE 112 ICELAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 149 TABLE 113 ICELAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 150 TABLE 114 ICELAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 150 TABLE 115 ICELAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 151 TABLE 116 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 151 TABLE 117 NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 152 TABLE 118 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 152 TABLE 119 NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 153 TABLE 120 NORWAY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 153 TABLE 121 NORWAY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) 154 TABLE 122 NORWAY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) 154 TABLE 123 NORWAY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) 155 TABLE 124 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) 155 TABLE 125 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) 156 TABLE 126 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) 156 TABLE 127 SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) 157 TABLE 128 SWEDEN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) 157 TABLE 129 SWEDEN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 130 SWEDEN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 131 SWEDEN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 132 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION) TABLE 133 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME) TABLE 134 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) TABLE 135 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 136 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 137 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 138 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 139 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 140 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) TABLE 141 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (TEST VOLUME) TABLE 142 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 143 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 144 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION) TABLE 145 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 146 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 147 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 148 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 149 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 150 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 151 INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 152 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION) TABLE 153 INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 154 INDIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 155 INDIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 156 INDIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 157 INDIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 158 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 159 JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 160 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION) TABLE 161 JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 162 JAPAN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 163 JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 164 JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 165 JAPAN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 166 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 167 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 168 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION) TABLE 169 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 170 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 171 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 172 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 173 SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 174 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 175 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 176 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION) TABLE 177 AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 178 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 179 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 180 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 181 AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 182 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION) TABLE 183 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME) TABLE 184 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION) TABLE 185 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME) TABLE 186 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION) TABLE 187 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION) TABLE 188 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION) TABLE 189 REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION) TABLE 190 PRODUCT/SERVICE LAUNCH TABLE 191 ACQUISITION/EXPANSION TABLE 192 ACCREDITATION TABLE 193 COLLABORATION/ PARTNERSHIP TABLE 194 QIAGEN: PRODUCTS AND SERVICES OFFERED TABLE 195 QIAGEN: KEY DEVELOPMENTS TABLE 196 BIO-TECHNE: PRODUCTS AND SERVICES OFFERED TABLE 197 BIOMÉRIEUX: PRODUCTS AND SERVICES OFFERED TABLE 198 BIOMÉRIEUX: PRODUCTS OFFERED TABLE 199 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED TABLE 200 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED TABLE 201 NG BIOTECH: PRODUCTS OFFERED TABLE 202 THERMO FISHER SCIENTIFIC INC.: PRODUCTS AND SERVICES OFFERED TABLE 203 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS TABLE 204 ILLUMINA, INC.: PRODUCTS AND SERVICES OFFERED TABLE 205 ILLUMINA, INC.: KEY DEVELOPMENTS TABLE 206 AGILENT TECHNOLOGIES, INC.: PRODUCTS AND SERVICES OFFERED TABLE 207 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS TABLE 208 FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ): PRODUCTS AND SERVICES OFFERED TABLE 209 MYRIAD GENETICS, INC.: PRODUCTS AND SERVICES OFFERED TABLE 210 MYRIAD GENETICS, INC.: KEY DEVELOPMENTS LIST OF FIGURES FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET: STRUCTURE 23 FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 42 FIGURE 2 GLOBAL COMPANION DIAGNOSTICS MARKET DRIVER: IMPACT ANALYSIS 44 FIGURE 3 GLOBAL COMPANION DIAGNOSTICS MARKET RESTRAINT: IMPACT ANALYSIS 46 FIGURE 4 PORTER'S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET 49 FIGURE 1 GLOBAL MARKET SHARE ANALYSIS: BY DRUG, 2024 55 FIGURE 2 NORTH AMERICA MARKET SHARE ANALYSIS: BY DRUG, 2024 56 FIGURE 3 US MARKET SHARE ANALYSIS: BY DRUG, 2024 56 FIGURE 4 EUROPE MARKET SHARE ANALYSIS: BY DRUG, 2024 57 FIGURE 5 GERMANY MARKET SHARE ANALYSIS: BY DRUG, 2024 57 FIGURE 6 UK MARKET SHARE ANALYSIS: BY DRUG, 2024 58 FIGURE 7 ASIA-PACIFIC MARKET SHARE ANALYSIS: BY DRUG, 2024 58 FIGURE 8 CHINA MARKET SHARE ANALYSIS: BY DRUG, 2024 59 FIGURE 9 INDIA MARKET SHARE ANALYSIS: BY DRUG, 2024 59 FIGURE 10 JAPAN MARKET SHARE ANALYSIS: BY DRUG, 2024 60 FIGURE 11 GLOBAL MARKET SHARE ANALYSIS: BY CLONE, 2024 61 FIGURE 12 NORTH AMERICA MARKET SHARE ANALYSIS: BY CLONE, 2024 61 FIGURE 13 US MARKET SHARE ANALYSIS: BY CLONE, 2024 62 FIGURE 14 EUROPE MARKET SHARE ANALYSIS: BY CLONE, 2024 62 FIGURE 15 GERMANY MARKET SHARE ANALYSIS: BY CLONE, 2024 63 FIGURE 16 UK MARKET SHARE ANALYSIS: BY CLONE, 2024 63 FIGURE 17 ASIA-PACIFIC MARKET SHARE ANALYSIS: BY CLONE, 2024 64 FIGURE 18 INDIA MARKET SHARE ANALYSIS: BY CLONE, 2024 64 FIGURE 19 JAPAN MARKET SHARE ANALYSIS: BY CLONE, 2024 65 FIGURE 20 GLOBAL COMPANION DIAGNOSTICS MARKET, TEST TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 69 FIGURE 21 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION) 70 FIGURE 22 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TEST TYPE, 2024 71 FIGURE 23 GLOBAL COMPANION DIAGNOSTICS MARKET, PRODUCT & SERVICES SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 76 FIGURE 24 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION) 77 FIGURE 25 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY PRODUCT & SERVICES, 2024 78 FIGURE 26 GLOBAL COMPANION DIAGNOSTICS MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 80 FIGURE 27 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION) 81 FIGURE 28 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TECHNOLOGY, 2024 82 FIGURE 29 GLOBAL COMPANION DIAGNOSTICS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 84 FIGURE 30 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION 2024 & 2035 (USD MILLION) 85 FIGURE 31 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY INDICATION, 2024 86 FIGURE 32 GLOBAL COMPANION DIAGNOSTICS MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 89 FIGURE 33 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER 2024 & 2035 (USD MILLION) 90 FIGURE 34 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY END USER, 2024 91 FIGURE 35 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 & 2035 (USD MILLION) 93 FIGURE 36 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY REGION, 2024 FIGURE 37 NORTH AMERICA MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION) FIGURE 38 NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) FIGURE 39 NORTH AMERICA COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024 FIGURE 40 EUROPE MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION) FIGURE 41 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) FIGURE 42 EUROPE: COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024 FIGURE 43 ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION) FIGURE 44 ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION) FIGURE 45 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024 FIGURE 46 GLOBAL COMPANION DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 FIGURE 47 COMPETITOR DASHBOARD: GLOBAL COMPANION DIAGNOSTICS MARKET FIGURE 48 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT FIGURE 49 QIAGEN: SWOT ANALYSIS FIGURE 50 BIO-TECHNE: FINANCIAL OVERVIEW SNAPSHOT FIGURE 51 BIO-TECHNE: SWOT ANALYSIS FIGURE 52 BIOMÉRIEUX: FINANCIAL OVERVIEW SNAPSHOT FIGURE 53 BIOMÉRIEUX: SWOT ANALYSIS FIGURE 54 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 55 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS FIGURE 56 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 57 AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT SOURCE: ANNUAL REPORT, PRESS RELEASES, AND MRFR ANALYSIS FIGURE 58 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS FIGURE 59 F. HOFFMANN-LA ROCHE LTD (FOUNDATION MEDICINE INC.): FINANCIAL OVERVIEW SNAPSHOT FIGURE 60 MYRIAD GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

提及公司

QiagenBio-TechneBiomérieuxLeica Biosystems Nussloch GmbHNG BiotechThermo Fisher Scientific Inc.IlluminaInc.Agilent TechnologiesInc.Foundation Medicine Inc. (F. Hoffmann-la Roche Ltd )Myriad GeneticsInc

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們